Chewy's shares rose 1.9% in premarket trading after the company reported Q2 adjusted earnings of $0.36 per share, matching analyst expectations, and revenue of $3.33 billion, slightly above estimates. Management raised the full-year 2027 revenue forecast to a range of $13.46 billion to $13.57 billion, surpassing Wall Street's midpoint estimate. Despite a 34% stock decline over the past year, the upgraded guidance provided a positive outlook for investors. The company expects Q3 revenue to be in line with analyst projections, maintaining steady growth and profitability amid challenging market conditions.
Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
K2 Vision has completed over 5,000 procedures using the Light Adjustable Lens (LAL), making it the highest-volume practice worldwide for this technology. The LAL is unique because it can be adjusted after implantation to fine-tune vision based on the...
BlackRock, Inc. disclosed that its shareholding in Fagron NV dropped below the 3% threshold to 2.96% after selling some voting securities, despite acquiring equivalent financial instruments. As of October 12, 2026, BlackRock holds 2,015,779 voting ri...
